ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
March 03, 2021 00:42 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
March 01, 2021 16:01 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 01, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel,...
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 05:34 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
October 22, 2020 07:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Atopic Dermatitis Treatment Market to Grow Remarkably with Rising Awareness About Skin Problems, says Fortune Business Insights
September 21, 2020 07:35 ET
|
Fortune Business Insights
Pune, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The increasing advancement in atopic dermatitis and its rising prevalence are boosting the global atopic dermatitis treatment market, predicts Fortune...
ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study
September 21, 2020 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
August 24, 2020 03:27 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
August 11, 2020 04:06 ET
|
Kymab Group Ltd
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...